Neumora Therapeutics (NMRA) Asset Writedowns and Impairment (2025)
Neumora Therapeutics (NMRA) posted quarterly Asset Writedowns and Impairment of $217000.0 for Q4 2025, up 1133.33% year-over-year from $17594.6 in Q4 2024, and up 1133.33% quarter-over-quarter from -$21000.0 in Q4 2024.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Asset Writedowns and Impairment (2025) Analysis & Trends
Neumora Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $217000.0 for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment rose 1133.33% year-over-year to $217000.0; the TTM figure through Dec 2025 stood at $217000.0 (changed N/A YoY), while the FY2025 annual figure was $595000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $217000.0, up from -$21000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $217000.0 in Q4 2025, with the low at -$21000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Neumora Therapeutics | 243.49 Mn | 243.49 Mn | - |